Haba Laboratories Inc

Haba Laboratories Inc maintains a strong liquidity position, with a current ratio of 3.4 and cash and equivalents amounting to ¥4.74 billion, representing 38.4% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 10.8%, which is above the median for the Personal Products industry. The price-to-book ratio of 0.72 suggests the company is trading at a discount to its book value, while the price-to-tangible-book ratio is identical, indicating no significant intangible asset premium. Profitability metrics show a return on equity (ROE) of 6.46% and a return on assets (ROA) of 4.67%, both below the industry median of 8.2% and 6.1%, respectively. The company's gross margin of 67.1% is in line with the industry median, but its operating margin of 5.05% is below the median of 6.8%, suggesting inefficiencies in cost control or pricing power. The company's revenue is concentrated in its core cosmetics and dietary supplements segments, with no disclosed geographic diversification. The top customer concentration is not disclosed, but the company's wholesale distribution model suggests exposure to a limited number of retail partners. This concentration could pose a risk if key customers reduce orders or shift to competitors. Looking ahead, the company's revenue is projected to grow by 3.2% in the current fiscal year and 2.1% in the next, based on analyst estimates and historical trends. Free cash flow is expected to remain stable, with capital expenditures projected to remain negative, indicating asset optimization rather than expansion. The company's operating cash flow of ¥1.62 billion supports its liquidity position and provides flexibility for dividends or share repurchases. Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 0.2 is well below the industry median of 0.5, indicating a conservative capital structure. However, the company's reliance on wholesale distribution and limited geographic diversification could expose it to supply chain or regional demand shocks. Recent events include the filing of its latest financial results, which showed revenue of ¥12.06 billion and EPS of ¥152.47. No material changes in management, strategy, or regulatory environment were disclosed in the latest filings. The company's retail operations and direct-to-consumer channels remain stable, with no significant disruptions reported.